1. Home
  2. RYTM vs GLBE Comparison

RYTM vs GLBE Comparison

Compare RYTM & GLBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • GLBE
  • Stock Information
  • Founded
  • RYTM 2008
  • GLBE 2013
  • Country
  • RYTM United States
  • GLBE Israel
  • Employees
  • RYTM 283
  • GLBE N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • GLBE Computer Software: Prepackaged Software
  • Sector
  • RYTM Health Care
  • GLBE Technology
  • Exchange
  • RYTM Nasdaq
  • GLBE Nasdaq
  • Market Cap
  • RYTM 6.9B
  • GLBE 6.0B
  • IPO Year
  • RYTM 2017
  • GLBE 2021
  • Fundamental
  • Price
  • RYTM $102.12
  • GLBE $35.78
  • Analyst Decision
  • RYTM Strong Buy
  • GLBE Buy
  • Analyst Count
  • RYTM 13
  • GLBE 13
  • Target Price
  • RYTM $101.92
  • GLBE $49.38
  • AVG Volume (30 Days)
  • RYTM 550.8K
  • GLBE 1.9M
  • Earning Date
  • RYTM 11-04-2025
  • GLBE 08-13-2025
  • Dividend Yield
  • RYTM N/A
  • GLBE N/A
  • EPS Growth
  • RYTM N/A
  • GLBE N/A
  • EPS
  • RYTM N/A
  • GLBE N/A
  • Revenue
  • RYTM $156,287,000.00
  • GLBE $843,642,000.00
  • Revenue This Year
  • RYTM $44.69
  • GLBE $28.25
  • Revenue Next Year
  • RYTM $63.53
  • GLBE $24.61
  • P/E Ratio
  • RYTM N/A
  • GLBE N/A
  • Revenue Growth
  • RYTM 53.55
  • GLBE 33.30
  • 52 Week Low
  • RYTM $45.91
  • GLBE $26.64
  • 52 Week High
  • RYTM $106.52
  • GLBE $63.69
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 60.62
  • GLBE 61.42
  • Support Level
  • RYTM $101.45
  • GLBE $32.52
  • Resistance Level
  • RYTM $106.52
  • GLBE $34.37
  • Average True Range (ATR)
  • RYTM 3.12
  • GLBE 1.17
  • MACD
  • RYTM -0.43
  • GLBE 0.36
  • Stochastic Oscillator
  • RYTM 65.84
  • GLBE 98.06

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About GLBE Global-E Online Ltd.

Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from and anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.

Share on Social Networks: